Cargando…
Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study
OBJECTIVE: The objective of this study is to determine the prevalence and predictors of sickness absence (SA) and disability pension (DP) in women with metastatic breast cancer (mBC). METHODS: Data were obtained from Swedish registers concerning 1,240 adult women diagnosed 1997–2011 with mBC, from 1...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541357/ https://www.ncbi.nlm.nih.gov/pubmed/35621269 http://dx.doi.org/10.1111/ecc.13626 |
_version_ | 1784803906827583488 |
---|---|
author | Altena, Renske Gernaat, Sofie A. M. Wilking, Ulla Kiani, Narsis A. Johnsson, Aina Hedayati, Elham |
author_facet | Altena, Renske Gernaat, Sofie A. M. Wilking, Ulla Kiani, Narsis A. Johnsson, Aina Hedayati, Elham |
author_sort | Altena, Renske |
collection | PubMed |
description | OBJECTIVE: The objective of this study is to determine the prevalence and predictors of sickness absence (SA) and disability pension (DP) in women with metastatic breast cancer (mBC). METHODS: Data were obtained from Swedish registers concerning 1,240 adult women diagnosed 1997–2011 with mBC, from 1 year before (y−1) to 2 (y1) and 2 (y2) years after diagnosis. SA and DP prevalence was calculated. Odds ratios (AOR) were determined for factors associated with using long‐term (SA > 180 days or DP > 0 days) sickness benefits. RESULTS: Prevalence of SA and DP was 56.0% and 24.8% during y−1, 69.9% and 28.9% during y1, and 64.0% and 34.7% during y2, respectively. Odds of using long‐term sickness benefits were higher y1 and y2 in patients using long‐term sickness benefits the year before diagnosis (AOR = 3.82, 95% CI 2.91–5.02; AOR = 4.31, 95% CI 2.96–6.29, respectively) and y2 in patients with mBC diagnosis 1997–2000 (AOR = 1.84, 95% CI 1.10–3.08) and using long‐term sickness benefits the year after diagnosis (AOR = 22.10, 95% CI 14.33–34.22). CONCLUSIONS: The prevalence of sickness benefit utilisation was high and increased after mBC diagnosis, particularly for patients using long‐term sickness benefits prior to diagnosis. Additional study is needed to determine factors that might reduce the need for sickness benefits and enhance work ability in these patients. |
format | Online Article Text |
id | pubmed-9541357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95413572022-10-14 Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study Altena, Renske Gernaat, Sofie A. M. Wilking, Ulla Kiani, Narsis A. Johnsson, Aina Hedayati, Elham Eur J Cancer Care (Engl) Original Articles OBJECTIVE: The objective of this study is to determine the prevalence and predictors of sickness absence (SA) and disability pension (DP) in women with metastatic breast cancer (mBC). METHODS: Data were obtained from Swedish registers concerning 1,240 adult women diagnosed 1997–2011 with mBC, from 1 year before (y−1) to 2 (y1) and 2 (y2) years after diagnosis. SA and DP prevalence was calculated. Odds ratios (AOR) were determined for factors associated with using long‐term (SA > 180 days or DP > 0 days) sickness benefits. RESULTS: Prevalence of SA and DP was 56.0% and 24.8% during y−1, 69.9% and 28.9% during y1, and 64.0% and 34.7% during y2, respectively. Odds of using long‐term sickness benefits were higher y1 and y2 in patients using long‐term sickness benefits the year before diagnosis (AOR = 3.82, 95% CI 2.91–5.02; AOR = 4.31, 95% CI 2.96–6.29, respectively) and y2 in patients with mBC diagnosis 1997–2000 (AOR = 1.84, 95% CI 1.10–3.08) and using long‐term sickness benefits the year after diagnosis (AOR = 22.10, 95% CI 14.33–34.22). CONCLUSIONS: The prevalence of sickness benefit utilisation was high and increased after mBC diagnosis, particularly for patients using long‐term sickness benefits prior to diagnosis. Additional study is needed to determine factors that might reduce the need for sickness benefits and enhance work ability in these patients. John Wiley and Sons Inc. 2022-05-27 2022-09 /pmc/articles/PMC9541357/ /pubmed/35621269 http://dx.doi.org/10.1111/ecc.13626 Text en © 2022 The Authors. European Journal of Cancer Care published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Altena, Renske Gernaat, Sofie A. M. Wilking, Ulla Kiani, Narsis A. Johnsson, Aina Hedayati, Elham Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study |
title | Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study |
title_full | Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study |
title_fullStr | Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study |
title_full_unstemmed | Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study |
title_short | Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study |
title_sort | use of sickness benefits by patients with metastatic breast cancer—a swedish cohort study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541357/ https://www.ncbi.nlm.nih.gov/pubmed/35621269 http://dx.doi.org/10.1111/ecc.13626 |
work_keys_str_mv | AT altenarenske useofsicknessbenefitsbypatientswithmetastaticbreastcanceraswedishcohortstudy AT gernaatsofieam useofsicknessbenefitsbypatientswithmetastaticbreastcanceraswedishcohortstudy AT wilkingulla useofsicknessbenefitsbypatientswithmetastaticbreastcanceraswedishcohortstudy AT kianinarsisa useofsicknessbenefitsbypatientswithmetastaticbreastcanceraswedishcohortstudy AT johnssonaina useofsicknessbenefitsbypatientswithmetastaticbreastcanceraswedishcohortstudy AT hedayatielham useofsicknessbenefitsbypatientswithmetastaticbreastcanceraswedishcohortstudy |